BSX-BOSTON SCIENTIFIC CORP

Boston Scientific Advances AFib Treatment with CE Mark Approval for Farapulse System and Sees Market Opportunities Amid Competitors' Challenges

Member Only Article

Wednesday

19 February, 2025

Boston Scientific is reshaping the AFib treatment landscape with its Farapulse system, achieving remarkable sales and positioning itself as a leader in the pulsed field ablation market. As competitors face hurdles, can Boston Scientific maintain its momentum and capitalize on this growing opportunity?

article image for BSX

Article Impact Score

0
50
100
Under­perform
Bear­ish
Neu­tral
Bull­ish
Out­perform
0
Key Takeaways
  • Loading...

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial
home-footer-logo

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.